Evaluation of treatment continuation with alosetron by IBS-D severity criteria

Current Medical Research and Opinion

Volumn 28, Issue 3, 2012, Pages 449-456

  Nicandro, Jean Paul ^a   Shin, Paul ^a   Chuang, Emil ^a  

^a Prometheus Laboratories Inc   (United States)

Author keywords

Alosetron; Diarrhea predominant irritable bowel syndrome; Patient follow up study; Severity criteria; Treatment continuation

Indexed keywords

ALOSETRON;

ADULT; AGED; ARTICLE; BLOATING; DISEASE SEVERITY; DRUG INFORMATION; FECES INCONTINENCE; FEMALE; FOLLOW UP; HUMAN; IRRITABLE COLON; MAJOR CLINICAL STUDY; MALE; QUESTIONNAIRE; STOMACH CRAMPS; STOMACH DISEASE;

ADOLESCENT; ADULT; AGED; CARBOLINES; DIARRHEA; FECAL INCONTINENCE; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL AGENTS; HUMANS; IRRITABLE BOWEL SYNDROME; MIDDLE AGED; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84858218039     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2011.653435     Document Type: Article

References (8)

1. Ford AC, Brandt LJ, Young C, et al. Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: Systematic review and meta-analysis. Am J Gastroenterol 2009;104:1831-43
2. U.S. Food and Drug Administration. Lotronex product information. 2000. Available at: Http://www.accessdata.fda.gov/drugsatfda-docs/label/2000/21107lbl. pdf [Last accessed 31 July 2011]
3. Miller D, Bennett L, Hollis K, et al. A patient follow-up survey programme for alosetron: Assessing compliance to and effectiveness of the risk management programme. Aliment Pharmacol Ther 2006;24: 869-78
4. Tennis P, Andrews E, Hickman P, et al. The relationship between dosing of alosetron and discontinuation patterns reported by patients participating in a follow-up programme. Aliment Pharmacol Ther 2007; 25:317-22
5. LOTRONEX (alosetron hydrochloride) prescribing information. 2010. Available at: Http://www.lotronex.com/hcp/-docs/Lotronex-PI.pdf [Last accessed 31 July 2011]
6. Chang L, Tong K, Ameen V. Ischemic colitis and complications of constipation associated with the use of alosetron under a risk management plan: Clinical characteristics, outcomes, and incidences. Am J Gastroenterol 2010; 105:866-75
7. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81
8. Brandt L, Chey W, Foxx-Orenstein A, et al. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol 2009;104(Suppl 1):S1-35